Posaconazole

被引:138
作者
Keating, GM [1 ]
机构
[1] Adis Int Ltd, Auckland, New Zealand
关键词
D O I
10.2165/00003495-200565110-00007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Posaconazole is a triazole antifungal agent, administered as an oral suspension, with an extended spectrum of in vitro activity. Posaconazole 800 mg/day demonstrated clinically relevant activity against a range of fungi in patients with invasive fungal infections who were refractory to, or intolerant of, other antifungal therapy in an open-label, multicentre, phase III study (330 patients received posaconazole and 279 patients served as external controls). In aspergillosis, the global response success rate at the end-of-therapy visit.(primary endpoint) was significantly higher in posaconazole recipients than in external controls (42% vs 26%). Posaconazole was also associated with overall success rates of 54% in zygomycosis, 46% in fusariosis, 43% in Pseudallescheria infection, 80% in phaeohyphomycosis and 100% in histoplasmosis. Success rates were 48% in refractory candidiasis, 69% in refractory coccidioidomycosis, 48% in refractory cryptococcal infection and 82% in refractory chromoblastomycosis or mycetoma. Posaconazole also demonstrated potential in febrile neutropenia in an open-label phase 11 study (success rate of 81% 7 days after the end of treatment). In a noncomparative, multicentre, phase III study in patients with advanced HIV infection who had azole-refractory oropharyngeal and/or oesophageal candidiasis, posaconazole 400 or 800 mg/day resulted in a clinical response in 132 of 176 patients (75%). Oral posaconazole suspension was generally well tolerated in patients with invasive fungal infections, including patients who received treatment for > 1 year.
引用
收藏
页码:1553 / 1567
页数:15
相关论文
共 100 条
[71]  
Opperman T.J., 2003, 43 ANN INT C ANT AG, V43, P255
[72]   In vitro antifungal susceptibilities of Trichosporon species [J].
Paphitou, NI ;
Ostrosky-Zeichner, L ;
Paetznick, VL ;
Rodriguez, JR ;
Chen, E ;
Rex, JH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :1144-1146
[73]   In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans [J].
Perfect, JR ;
Cox, GM ;
Dodge, RK ;
Schell, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1910-1913
[74]  
PERFECT JR, 2004, 42 ANN M INF DIS SOC
[75]   Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: Correlation with galactomannan antigenemia [J].
Petraitiene, R ;
Petraitis, V ;
Groll, AH ;
Sein, T ;
Piscitelli, S ;
Candelario, M ;
Field-Ridley, A ;
Avila, N ;
Bacher, J ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :857-869
[76]   Rare and emerging opportunistic fungal pathogens:: Concern for resistance beyond Candida albicans and Aspergillus fumigatus [J].
Pfaller, MA ;
Diekema, DJ .
JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (10) :4419-4431
[77]   In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program [J].
Pfaller, MA ;
Messer, SA ;
Boyken, L ;
Hollis, RJ ;
Rice, C ;
Tendolkar, S ;
Diekema, DJ .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 48 (03) :201-205
[78]   In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans [J].
Pfaller, MA ;
Messer, SA ;
Hollis, RJ ;
Jones, RN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2862-2864
[79]   Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi:: Report from SENTRY Antimicrobial Surveillance Program, 2000 [J].
Pfaller, MA ;
Messer, SA ;
Hollis, RJ ;
Jones, RN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :1032-1037
[80]  
PITISUTTITHUM P, 2003, 43 INT C ANT AG CHEM